image

The best stocks to buy since 1993

Latest issue now available

Incadea - 190p cash bid from Dealertrack; gain 128%

January 2015

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • INCA
  • Price:
  • 191p
Christmas came early for Incadea shareholders after a knockout offer by Dealertrack Technologies (NASDAQ; TRAK). Dealertrack is offering 190p cash per share, which values Incadea at £121.6m. Based on forecasts for the year to 31 December from N+1 Singer of sales, pretax profit and earnings of Eu56.3m, Eu4.9m and 6.1 cents respectively, it looks a superb premium. Dealertrack has received acceptances from 56.1% of shareholders. We tipped the shares in September ‘12 at 83.75p.  Accept the offer.  Gain 128%.  ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

LIMITED PERIOD OFFER

SUBSCRIBE TODAY AND SAVE £40 WITH OFFER CODE 40OFFSCSW

To access our archive of articles and to receive current issues you need to subscribe